A young boy with Duchenne muscular dystrophy died after an experimental gene-editing treatment in China — and the company behind it, Shanghai-based HuidaGene Therapeutics, waited almost a full year to tell anyone.
That's the story in one line.
Now let's unpack why it matters.
Duchenne muscular dystrophy, or DMD, is a brutal disease.
It's genetic, it mostly hits boys, and it slowly destroys muscle function until the body simply can't keep going.
There's no cure.
So when CRISPR gene-editing — the tech that can rewrite faulty DNA — offered a shot at fixing the root cause, families lined up.
HuidaGene was one of the companies racing to get there first, running ahead of similar efforts stuck in regulatory limbo in the United States.
The trial, called HG302, enrolled young boys — trial records point to ages 4 to 8 — at Shanghai Children's Medical Center.
In August 2025, one of them received a high dose of the therapy.
He developed a severe immune reaction.
That spiraled into acute respiratory distress syndrome.
He died.
HuidaGene only confirmed this publicly on August 5, 2026 — nearly twelve months later.
And the disclosure didn't come out of goodwill.
It came after a months-long investigation by health news outlet STAT, which kept pressing the company for answers while it stayed almost completely silent — no press releases, no updates, nothing, for over a year.
The company reportedly even quietly changed the trial's public status just five days before finally coming clean.
Here's the part that turns this from one bad trial into a pattern.
Weeks before HuidaGene's admission, it emerged that a 6-year-old girl had died in March 2025 in a completely separate, unrelated gene-editing study — this one run by researchers at Shanghai Jiao Tong University School of Medicine.
That death, too, sat undisclosed for months until it was reported.
Chinese authorities have now opened investigations into both cases.
Two child deaths. Two gene-editing trials. Two long silences. Same city.
The uncomfortable detail buried in all this: HuidaGene's trial was what's called an "investigator-initiated" study — run by hospital researchers rather than directly by pharma regulators.
China has a pathway that lets hospitals launch these trials without the kind of upfront government oversight that a full clinical trial application would require.
That pathway is exactly what let HuidaGene move faster than competitors elsewhere in the world.
Speed was the whole pitch.
Faster science, it turns out, can also mean thinner guardrails.
China has spent years positioning itself as a biotech powerhouse — cheaper trials, faster approvals, huge patient pools, and a government eager to win the race in cutting-edge fields like gene editing.
That strategy has produced real breakthroughs.
But it's also now producing real questions.
If a company can sit on a patient death for a year, in a disease that already devastates families desperate for any hope, what else isn't getting reported.
HuidaGene hasn't said what happens next for the therapy — whether the trial continues, whether other patients were affected, or whether the treatment gets shelved entirely.
For now, two grieving families, two ongoing government probes, and a biotech industry racing to build trust as fast as it's building CRISPR tools.
That trust just took a serious hit.
That's all for now!
